EPITOPES PREDOMINANTLY RETAINED ON THE CARCINOEMBRYONIC ANTIGEN MOLECULES IN PLASMA OF PATIENTS WITH MALIGNANT-TUMORS BUT NOT ON THOSE IN PLASMA OF NORMAL INDIVIDUALS

被引:20
作者
KUROKI, M
MURAKAMI, M
WAKISAKA, M
KROPWATOREK, A
OIKAWA, S
NAKAZATO, H
KOSAKI, G
MATSUOKA, Y
机构
[1] FUKUOKA UNIV,SCH MED,DEPT BIOCHEM 1,7-45-1 NANAKUMA,JONAN KU,FUKUOKA 81401,JAPAN
[2] SUNTORY INST BIOMED RES,SHIMAMOTO,OSAKA 618,JAPAN
[3] TOKYO METROPOLITAN KOMAGOME HOSP,BUNKYO KU,TOKYO 170,JAPAN
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 1992年 / 83卷 / 05期
关键词
CARCINOEMBRYONIC ANTIGEN; EPITOPE; MONOCLONAL ANTIBODY; CEA-DISTINCTIVE ANTIGENICITY; PLASMA CEA;
D O I
10.1111/j.1349-7006.1992.tb01957.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have previously reported that a group of monoclonal antibodies (MAbs) to carcinoembryonic antigen (CEA), designated Group F MAbs, are able to discriminate CEA in tumor tissues from normal fecal antigen-2, a soluble form CEA-counterpart in normal adult feces, and that the protein epitopes recognized by them are present on the domain A3-B3 of the CEA molecule. In this study, we further investigated the molecular localization of the epitopes recognized by the Group F MAbs using three new recombinant CEA proteins with restricted domain structures expressed in Chinese hamster ovary cells, and found that the epitopes for the Group F MAbs are present on domain B3 close to the anchoring device of the CEA molecule. The epitopes for the Group F MAbs were retained on the CEA molecules in the plasma of patients with malignant tumors and on the CEA molecules spontaneously released into the culture media from established tumor cell lines. However, a large part of the CEA molecules in the plasma of normal individuals were found to lack the epitopes for the Group F MAbs. These results provide a basis for the improved cancer diagnosis by using our CEA assay system utilizing a Group F MAb, and indicate the potential clinical utility of the Group F MAbs.
引用
收藏
页码:505 / 514
页数:10
相关论文
共 34 条
[1]  
BAYER EA, 1990, METHOD ENZYMOL, V184, P138
[2]  
COUNOYER D, 1988, CANCER RES, V48, P3153
[3]  
HAMMARSTROM S, 1989, CANCER RES, V49, P4852
[4]   A MONOCLONAL-ANTIBODY ENZYME-IMMUNOASSAY FOR SERUM CARCINOEMBRYONIC ANTIGEN WITH INCREASED SPECIFICITY FOR CARCINOMAS [J].
HEDIN, A ;
CARLSSON, L ;
BERGLUND, A ;
HAMMARSTROM, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (11) :3470-3474
[5]  
ICHIKI S, 1986, JPN J CANCER RES, V77, P462
[6]  
IKEDA S, 1992, MOL IMMUNOL, V29, P229
[7]  
KESSLER MJ, 1978, CANCER RES, V38, P1041
[8]   SEROLOGIC MAPPING AND BIOCHEMICAL-CHARACTERIZATION OF THE CARCINOEMBRYONIC ANTIGEN EPITOPES USING 14 DISTINCT MONOCLONAL-ANTIBODIES [J].
KUROKI, M ;
GREINER, JW ;
SIMPSON, JF ;
PRIMUS, FJ ;
GUADAGNI, F ;
SCHLOM, J .
INTERNATIONAL JOURNAL OF CANCER, 1989, 44 (02) :208-218
[9]   ACTIVE PRODUCTION AND MEMBRANE ANCHORING OF CARCINOEMBRYONIC ANTIGEN OBSERVED IN NORMAL COLON MUCOSA [J].
KUROKI, M ;
ARAKAWA, F ;
YAMAMOTO, H ;
SHIMURA, H ;
IKEHARA, Y ;
MATSUOKA, Y .
CANCER LETTERS, 1988, 43 (1-2) :151-157
[10]  
KUROKI M, 1990, CANCER RES, V50, P4872